Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Gross Profit (2016 - 2025)

Dexcom (DXCM) has disclosed Gross Profit for 16 consecutive years, with $792.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 20.88% to $792.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 billion, a 14.92% increase, with the full-year FY2025 number at $2.8 billion, up 14.92% from a year prior.
  • Gross Profit was $792.7 million for Q4 2025 at Dexcom, up from $731.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $792.7 million in Q4 2025 to a low of $343.9 million in Q1 2021.
  • A 5-year average of $554.6 million and a median of $554.2 million in 2023 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 46.81% in 2021, then fell 4.73% in 2024.
  • Dexcom's Gross Profit stood at $472.6 million in 2021, then rose by 14.54% to $541.3 million in 2022, then increased by 21.3% to $656.6 million in 2023, then dropped by 0.12% to $655.8 million in 2024, then increased by 20.88% to $792.7 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Gross Profit are $792.7 million (Q4 2025), $731.4 million (Q3 2025), and $688.8 million (Q2 2025).